Anemia Clinical Trial
Official title:
Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes
With the long-term public health goal of developing an effective micronutrient supplementation program to improve child health by improving iron and zinc status and decreasing morbidity due to diarrhea in areas with high rates of childhood malnutrition, we seek to determine the most efficacious method of decreasing childhood morbidity and mortality due to diarrhea in toddlers by re-examining the issue of iron and zinc interaction and determining if this interaction can be minimized by separate administration of iron and zinc supplementation.
Iron supplementation is used in reducing anemia and improving hemoglobin status. Zinc
supplementation is emerging as possibly an efficacious preventive measure in decreasing
incidence of severe diarrhea. Previous studies have suggested interactions of zinc and iron
when given together, reducing the effects of supplementation with both minerals. One study in
Peru has shown a decrease in interaction effect with separate supplementation of iron and
zinc in time when compared to iron administration alone or placebo; however, an evaluation of
clinical outcomes and zinc or iron status when iron and zinc are administered separately
compared to supplementation of zinc and iron together or each alone has not previously been
done. This trial will assess the effect of iron and zinc supplementation given on alternate
days compared with giving them together in a combined supplement.
We propose a randomized, double blind, placebo-controlled community trial of children 6-23
months in Mirzapur, Bangladesh. We will recruit and enroll 1000 children 6-23 months old who
are permanent residents of the selected villages. Each child will be randomly assigned to 1)
daily alternating zinc and placebo 2) daily alternating iron/folic acid and placebo 3) daily
alternating zinc/iron/folic acid and placebo 4) daily alternating zinc and iron/folic acid 5)
daily placebo. Primary outcomes will include incidence of severe diarrhea, evaluated weekly
for 6 months, hemoglobin, prevalence of anemia, and serum zinc.
Analysis of the data will be done to compare the effect of separate iron and zinc
supplementation as compared to combined iron and zinc supplementation as well as compared to
iron, zinc, or placebo single supplementation. We will evaluate the difference in incidence
rate of severe diarrhea, serum hemoglobin, percent anemia, and serum zinc. Since this will be
a randomized, double-blind, placebo controlled trial, differences in effect will be most
likely explained by the timing of supplement doses. If there is an improvement in clinical
and biochemical outcomes, this would be consistent with a decreased interaction of
absorption. If no difference is found, there may be another mechanism for the seeming
interaction of iron and zinc besides that of mutually inhibitory absorption in the intestine.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |